NGL Fine-Chem Limited

NGLFINE

INE887E01022

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:53 2024-06-14 am EDT			5-day change	1st Jan Change
2,404 ^INR	+2.97%		+4.64%	+7.75%

May. 28	Transcript : NGL Fine-Chem Limited, Q4 2024 Earnings Call, May 28, 2024
May. 22	NGL Fine-Chem Limited Recommends Final Dividend for the Year Ended March 31, 2024	CI

NGL Fine-Chem Limited Recommends Final Dividend for the Year Ended March 31, 2024

May 22, 2024 at 02:27 am EDT

NGL Fine-Chem Limited recommended final dividend of INR 1.75 per fully paid up equity share of INR 5 each for the financial year ended on March 31, 2024, at the AGM to be held on August 23, 2024.

Latest news about NGL Fine-Chem Limited

Transcript : NGL Fine-Chem Limited, Q4 2024 Earnings Call, May 28, 2024	May. 28
NGL Fine-Chem Limited Recommends Final Dividend for the Year Ended March 31, 2024	May. 22	CI
NGL Fine-Chem Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	May. 21	CI
NGL Fine-Chem Limited Approves the Appointment of Dhananjay Mungale as Independent Director	Apr. 19	CI
Crisil Keeps NGL Fine-Chem Rating at BBB+; Outlook Stable	Mar. 29	MT
NGL Fine-Chem Limited Announces Retirement of Milind Shinde as Independent Director, with Effect from March 31, 2024	Mar. 28	CI
NGL Fine-Chem Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 12	CI
Transcript : NGL Fine-Chem Limited, Q2 2024 Earnings Call, Nov 20, 2023	Nov. 20
NGL Fine-Chem Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-04	CI
Crisil Keeps SME 1 Rating on NGL Fine-Chem	23-07-18	MT
Transcript : NGL Fine-Chem Limited, Q4 2023 Earnings Call, May 19, 2023	23-05-19
NGL Fine-Chem Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23-05-15	CI
NGL Fine-Chem Limited Recommends Final Dividend for the Financial Year Ended on March 31, 2023, Payable on or After September 4, 2023	23-05-15	CI
ICRA Affirms NGL Fine-Chem Rating at BBB+	23-03-30	MT
NGL Fine-Chem Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-10	CI
Crisil Keeps NGL Fine-Chem Rating at BBB+; Lowers Outlook to Stable	23-01-11	MT
Transcript : NGL Fine-Chem Limited, Q3 2022 Earnings Call, Nov 17, 2022	22-11-17
NGL Fine-Chem Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-10-28	CI
Transcript : NGL Fine-Chem Limited, Q1 2023 Earnings Call, Aug 17, 2022	22-08-17
NGL Fine-Chem Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-11	CI
NGL Fine-Chem Limited Announces Resignation of K.V. Subramanian as Independent Director	22-08-10	CI
NGL Fine-Chem Limited Approves Final Dividend for the Financial Year Ended 31 March, 2022	22-07-01	CI
Crisil Keeps SME 1 Rating on NGL Fine-Chem; Shares Fall 5%	22-06-20	MT
Transcript : NGL Fine-Chem Limited, Q4 2022 Earnings Call, May 04, 2022	22-05-04
NGL Fine-Chem Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2022	22-05-02	CI

NGL Fine-Chem Limited is an India-based company, which is a manufacturer of pharmaceuticals and intermediates for use in veterinary and human health. The Company caters to various global companies to custom manufacture pharmaceuticals. Its products include APIs Animal Health, APIs Human Health, Intermediates and Specialty Chemicals and Finished Dosage Form. The APIs Animal Health products include Homidium Chloride, Nitroxynil, Clorsulon, Parvaquone, Buparvaquone, Isometamidium Chloride Hydrochloride, Toldimfos Sodium, Butaphosphan, Imidocarb Dipropionate, Triclabendazole, Rafoxanide, Diminazene Aceturate, S-Methoprene, Carprofen and others. The APIs Human Health products include Nitazoxanide and Atovaquone. The Intermediates and Specialty Chemicals product includes 1,4,7-Trimethyl-1,4,7-Triazacylononane and N-Ethyl Glucamine. The Finished Dosage Form products include Diminazene Aceturate Granules and Homidium Chloride Tablets. It has manufacturing plants located around Mumbai.

Sector

Pharmaceuticals

Calendar

2024-07-31 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Veterinary Drugs

	1st Jan change	Capi.
NGL FINE-CHEM LIMITED	+7.75%	178M
ZOETIS INC.	-13.93%	77.82B
ELANCO ANIMAL HEALTH INCORPORATED	+20.84%	8.91B
BLUESTAR ADISSEO COMPANY	+23.12%	3.6B
VIMIAN GROUP AB	+12.50%	1.67B
VETOQUINOL SA	-4.98%	1.23B
JINYU BIO-TECHNOLOGY CO., LTD.	-30.18%	1.16B
CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.	-31.11%	1.15B
WUHAN KEQIAN BIOLOGY CO.,LTD	-23.45%	1.01B
TIANJIN RINGPU BIO-TECHNOLOGY CO.,LTD.	-11.41%	916M